Status:
RECRUITING
Effects of Intrauterine Administration of Autologous PBMC on the Endometrial Cells Populations
Lead Sponsor:
Nadezhda Women's Health Hospital
Collaborating Sponsors:
Medical diagnostic laboratory ImunoVita
Conditions:
Female Infertility
Eligibility:
FEMALE
20-50 years
Phase:
NA
Brief Summary
The behaviour of the endometrium during its receptive phase is highly dependent on the endometrial cell type composition. Each cell type has its role in the endometrial preparation for the invading em...
Eligibility Criteria
Inclusion
- Participating in Assisted Reproduction Treatment
- Presenting altered endometrial immune profile
- Having primary infertility
- Having regular menstrual cycles
- Embryo transfer of euploid embryos
Exclusion
- Uterine pathologies
- Endometrial Bacterial infections
- Active endometrial inflammation
- Polycystic ovary syndrome
- Presence of auto anti-bodies such as anti-TPO, anti-TG, ACA, APA, ANA, and anti-dsDNA
- Presence of mutations involving the coagulation system such as deficiency of factor XII, Pro C, Pro S
- Cancer diagnostics
- Positive HIV, HCV or HBV tests
Key Trial Info
Start Date :
December 9 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 9 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05421364
Start Date
December 9 2023
End Date
December 9 2026
Last Update
May 21 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Nadezhda Women's Health Hospital
Sofia, Sofia, Bulgaria, 1373
2
Medical diagnostic laboratory Imunovita
Sofia, Bulgaria, 1373